Given the extensive expression of PDCD1, PD-L1, and CTAL-4, Subtype 2 was projected to align with immune checkpoint blockades (ICBs) therapy recommendation against the low response situation of the unscreened PAAD cohort currently(Morrison et al. 2018). The gene discussed is PDCD1; the disease is pancreatic adenocarcinoma.